Cargando…
Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial
This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double‐blinded, placebo‐controlled, parallel‐arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563761/ https://www.ncbi.nlm.nih.gov/pubmed/37823170 http://dx.doi.org/10.1002/fsn3.3530 |
_version_ | 1785118404434198528 |
---|---|
author | Rabizadeh, Soghra Heidari, Firouzeh Karimi, Reza Rajab, Armin Rahimi‐Dehgolan, Shahram Yadegar, Amirhossein Mohammadi, Fatemeh Mirmiranpour, Hossein Esteghamati, Alireza Nakhjavani, Manouchehr |
author_facet | Rabizadeh, Soghra Heidari, Firouzeh Karimi, Reza Rajab, Armin Rahimi‐Dehgolan, Shahram Yadegar, Amirhossein Mohammadi, Fatemeh Mirmiranpour, Hossein Esteghamati, Alireza Nakhjavani, Manouchehr |
author_sort | Rabizadeh, Soghra |
collection | PubMed |
description | This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double‐blinded, placebo‐controlled, parallel‐arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: n = 32, placebo: n = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low‐density lipoprotein (ox‐LDL), highly sensitive C‐reactive protein (hs‐CRP), tumor necrosis factor‐α (TNF‐α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (p‐value < .001) and AGEs (p‐value = .002) demonstrated a significant decrease after controlling for multiple confounders, including age, blood pressure, waist circumference, HbA1C, TG, and LDL‐C, while no significant changes were observed for AOPP (p‐value = .234) and ox‐LDL (p‐value = .480). The FRAP showed an increasing trend as an antioxidant marker but was not statistically significant (p‐value = .312). The hs‐CRP and TNF‐α had no significant changes (p‐value: .899 and .454, respectively). Also, no major adverse events were observed. Vitamin C supplementation may be beneficial in reducing AGEs and MDA in patients with T2D. |
format | Online Article Text |
id | pubmed-10563761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105637612023-10-11 Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial Rabizadeh, Soghra Heidari, Firouzeh Karimi, Reza Rajab, Armin Rahimi‐Dehgolan, Shahram Yadegar, Amirhossein Mohammadi, Fatemeh Mirmiranpour, Hossein Esteghamati, Alireza Nakhjavani, Manouchehr Food Sci Nutr Original Articles This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double‐blinded, placebo‐controlled, parallel‐arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: n = 32, placebo: n = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low‐density lipoprotein (ox‐LDL), highly sensitive C‐reactive protein (hs‐CRP), tumor necrosis factor‐α (TNF‐α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (p‐value < .001) and AGEs (p‐value = .002) demonstrated a significant decrease after controlling for multiple confounders, including age, blood pressure, waist circumference, HbA1C, TG, and LDL‐C, while no significant changes were observed for AOPP (p‐value = .234) and ox‐LDL (p‐value = .480). The FRAP showed an increasing trend as an antioxidant marker but was not statistically significant (p‐value = .312). The hs‐CRP and TNF‐α had no significant changes (p‐value: .899 and .454, respectively). Also, no major adverse events were observed. Vitamin C supplementation may be beneficial in reducing AGEs and MDA in patients with T2D. John Wiley and Sons Inc. 2023-06-30 /pmc/articles/PMC10563761/ /pubmed/37823170 http://dx.doi.org/10.1002/fsn3.3530 Text en © 2023 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Rabizadeh, Soghra Heidari, Firouzeh Karimi, Reza Rajab, Armin Rahimi‐Dehgolan, Shahram Yadegar, Amirhossein Mohammadi, Fatemeh Mirmiranpour, Hossein Esteghamati, Alireza Nakhjavani, Manouchehr Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title | Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title_full | Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title_fullStr | Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title_full_unstemmed | Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title_short | Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial |
title_sort | vitamin c supplementation lowers advanced glycation end products (ages) and malondialdehyde (mda) in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled clinical trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563761/ https://www.ncbi.nlm.nih.gov/pubmed/37823170 http://dx.doi.org/10.1002/fsn3.3530 |
work_keys_str_mv | AT rabizadehsoghra vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT heidarifirouzeh vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT karimireza vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT rajabarmin vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT rahimidehgolanshahram vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT yadegaramirhossein vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT mohammadifatemeh vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT mirmiranpourhossein vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT esteghamatialireza vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial AT nakhjavanimanouchehr vitamincsupplementationlowersadvancedglycationendproductsagesandmalondialdehydemdainpatientswithtype2diabetesarandomizeddoubleblindplacebocontrolledclinicaltrial |